Do You Take Statins? If Not, You May Be Soon

A change in guidelines for prescribing statins could boost sales for Merck (MRK) and AstraZeneca (AZN), and may someday increase demand for PCSK9 drugs from Regeneron (REGN), Amgen (AMGN), and Pfizer (PFE).

Mar 20, 2014 at 5:02PM

If you're over the age of 45 and are at risk of heart disease, your doctor may start recommending you take statins like Pfizer's (NYSE:PFE) Lipitor, Merck's (NYSE:MRK) Zetia, or AstraZeneca's (NYSE:AZN) Crestor. Those drugs are part of a class of cholesterol fighting compounds known as statins that are already being prescribed to roughly a third of U.S. adults. 

In November, guidance provided to doctors by the American Heart Association recommended the use of statins be expanded from those already showing signs of heart disease to those that may also be at risk of developing heart disease based on factors like weight, age, and blood pressure.

That shift in guidance may increase the number of patients taking statins to nearly half of all U.S. adults. However, the benefit of this change may not be limited to the manufacturers of statins. It may also eventually boost the use of next-generation cholesterol fighting compounds being developed by Regeneron (NASDAQ:REGN)Amgen (NASDAQ:AMGN), and Pfizer.

Curbing cholesterol
According to research published in the New England Journal of Medicine, statins may be prescribed to 12 million more people following the revamped guidance. More than 10 million of those 12 million are likely to be people who have no cardiovascular disease currently, but may have heart disease in the future. 

The biggest impact will be among those aged 60 and up. Under the previous guidelines, roughly 30% of those in that age group were deemed eligible for statin therapy. Now, more than 80% will be considered eligible.

That's a huge increase in the patient population served by these medications, and it may mark the biggest shift in their use since they were first approved in the 1990s. But what do statins do?

Cholesterol is important to a body's normal functioning. It's a necessary building block for every cell in our bodies. But sometimes, cholesterol can build up in the wrong places, like our arteries. If those buildups become blockages, patients can suffer a stroke or heart attack.

So, while some cholesterol is necessary, controlling "bad" cholesterol, or LDL, can help prevent those dangerous buildups. To do this, drugmakers developed statins. Statins encourage the liver -- the organ responsible for creating 70% of our body's cholesterol -- to remove LDL from the bloodstream by reducing the production of a cholesterol creating enzyme. In studies, statins successfully lowered the amount of bad cholesterol enough to reduce the chance of heart disease by 60%. 

Based on that success, doctors turned statinsinto the most widely sold treatments in America, resulting in more than $20 billion in annual sales for statin drug manufacturers at their height. 

A maturing market for statins
The most successful statin of all-time was Pfizer's Lipitor. Lipitor was the most widely prescribed statin in the U.S., and the top-selling drug of all time. Lipitor generated more than $125 billion in sales for Pfizer between 1997 and 2011,and prior to losing patent exclusivity, Lipitor's sales were eclipsing $12 billion a year.

But Lipitor isn't the only statin that ranks among the best-selling therapies. According to IMS, Merck's Zetia, for example, is the 28th best-selling drug in the U.S., with sales of $444 million in the fourth quarter.Zetia's total global sales were $2.7 billion;however, that pales in comparison to AstraZeneca's Crestor.

Crestor's sales totaled $1.5 billion in the fourth quarter, bringing sales of Astra's cholesterol fighter to $5.6 billion last year. That made Crestor the fourth best-selling drug in America in 2013, according to IMS.

A lot of soon-to-be prescribed statin users will likely find themselves treated with generic versions of Lipitor, but some will end up with prescriptions for Zetia or Crestor instead. That suggests sales for both drugs may climb in the coming year.

Developing the next cholesterol busting drug
Statins have been widely used, but they don't work for everyone. In some cases, patients don't respond to the therapy, and in others, side affects like memory loss or muscle weakness may occur.

That has drug developers hard at work developing drugs that can either replace or improve statin therapy. The most advanced of this research centers around the PCSK9 gene.

Statins have been shown to boost the amount of the PCSK9 protein created by that gene, and PCSK9 protein has been associated with reducing statin's effectiveness. As a result, companies including Regeneron, Amgen, and Pfizer are conducting trials across thousands of patients for PCSK9 inhibiting therapies.

Both Regeneron and Amgen's drugs are closest to convincing regulators to approve their use. Regeneron, which is working with Sanofi on the new drug, reported its alirocumab PCSK9 drug reduced bad cholesterol in 94% of patients during phase 3 trials. On average, patients treated with alirocumab saw their LDL levels fall by 47% after 24 weeks.

During phase 2 trials, Amgen's PCSK9 drug, labeled AMG-145 or evolucumab, reduced bad cholesterol by 40% to 59% versus just 0.1% to 0.5% for patients treated with placebo. While Amgen hasn't released the exact numbers for its phase 3 trials, it has indicated it saw similar results.

Over at Pfizer, its PCSK9 compound, RN316, is similarly successful, lowering LDL by 56% after 12 weeks. 

Fool-worthy final thoughts
The American Heart Association estimates Americans spending on cardiovascular disease will triple by 2030 to more than $800 billion as the number of people with the disease grows to roughly 40% of the population.

In order to control that spending, doctors will have to proactively treat patients that are at risk of developing the disease. While a lot of that activity will center on promoting healthier lifestyles, many will also turn to statin therapy.

Assuming Regeneron, Amgen, and Pfizer are able to usher their new PCSK9 drugs to market, those drugs may soon be prescribed alongside, or instead of, statins in some cardiovascular patients. Of course, not every patient will benefit from the increased use of these drugs, but for many, their use may prove life-saving. After all, heart disease is responsible for roughly one in four deaths every year.  

Heart disease is one reason for health care reform. Here's what else you should know.
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days.

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers